Q3 2021 Investor Relations Results

Participants Financial review Conclusion Appendix Company overview Pharmaceuticals Oncology Financial performance Innovation: Pipeline overview Novartis pipeline in Phase 1 (2 of 2) Immunology, Hepatology, Dermatology Code Name CEE321 CEE321 FIA586 FIA586 MHS552 MHS552 MHV370 MHV370 Mechanism Pan JAK inhibitor NG1226 NG1226 Neuroscience Code Name LMI070 Branaplam NIO752 NIO752 Indication(s) Atopic dermatitis Non-alcoholic steatohepatitis (NASH) Autoimmune indications Sjögren's Tendinopathy Systemic lupus erythematosus Mechanism Indication(s) mRNA splicing modulator Huntington's disease Tau antagonist Progressive supranuclear palsy Respiratory & Allergy Name Code LTP001 LTP001 NCJ424 NCJ424 Mechanism References Innovation: Clinical trials 34 lead indications Lead indication Indication(s) Respiratory diseases Respiratory diseases Cardiovascular, Renal, Metabolism Code Name MBL949 MBL949 Mechanism Indication(s) Obesity related diseases Global Health Ophthalmology Code MHU650 Name Mechanism Indication(s) KAF156 MHU650 Diabetic eye diseases INE963 Code Name EYU688 EYU688 ganaplacide INE963 Mechanism NS4B inhibitor 53 Investor Relations | Q3 2021 Results Indication(s) Dengue Malaria prophylaxis Malaria, uncomplicated NOVARTIS | Reimagining Medicine

View entire presentation